RECURRENT GLIOBLASTOMA MULTIFORME TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

Recurrent Glioblastoma Multiforme Treatment Market, By Treatment (Oral Medication, Radiosensitizers, Nitrosoureas Drugs, Chemotherapy ), By Type (Grade II or Grade III, Grade IV, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In: 02 Apr, 2026
Code: CMI682
Page number: 152
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range : 2020 - 2024
- Base Year : 2025
- Estimated Year : 2026
- Forecast Period : 2026 - 2033

Glioblastoma multiforme or GBM is an aggressive and the most common form of brain cancer that involves glial cells. Gliomas are rapidly developing tumors that develop from the star-shaped glial cells present in the spinal cord or brain. Recurrent glioblastoma multiforme is a possibility of reoccurrence of GBM after tumor surgery. This is because it is difficult to wholly remove the tumor during surgery and there is always a possibility that after a period of remission, cancer might recur. The symptoms of GBM include constant headaches, seizures, vomiting, difficulty in speaking, and double or blurred vision.

Market Dynamics

The rising incidence of brain cancers is expected to drive the recurrent glioblastoma multiforme treatment market growth over the forecast period. Although, researchers believe that egentic mutations may cause this disease, symptoms include seizures, change in mood, loss of appetite, double or blurred vision, change in ability to think and difficulty in speech. According to the statistics provided by the World Health Organization (WHO), each year, around 5 million people are diagnosed with epilepsy across the globe.

Moreover, tuberous sclerosis, neurofibromatosis, von-hippel-lindau disease, turcot syndrome, and Li-fraumeni syndrome are some of the genetic disorders related to the increasing prevalence of gliomas, which is expected to fuel the market growth during the forecast period.

Furthermore, key players in the market are increasingly investing in research & development to develop, create, and commercialize novel drugs, which is expected to create lucrative growth opportunities for the global recurrent glioblastoma multiforme treatment market in the near future. However, lack of effective therapies and the inability of drugs to effectively prevent tumor reoccurrence are predicted to restrict the market growth over the forecast period.

Key features of the study

This report provides in-depth analysis of the global recurrent glioblastoma multiforme treatment market, market size (USD Bn), and compound annual growth rate (CAGR (%)) for the forecast period: 2026-2033, considering 2025 as the base year
It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
It profiles key players in the global recurrent glioblastoma multiforme treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
Key players covered as a part of this study include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
The global recurrent glioblastoma multiforme treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for recurrent glioblastoma multiforme treatment market, research and consulting firms, new entrants, and financial analysts.

Market Segmentation

By Treatment
- Oral Medications
- Radiosensitizers
- Nitrosoureas Drugs
- Chemotherapy
By Type
- Grade II or Grade III
- Grade IV
- Others
By Region
- North America
  - U.S.
  - Canada
- Latin America
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
- Europe
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Middle East & Africa
  - GCC Countries
  - Israel
  - Rest of Middle East & Africa
Key Players
- GlaxoSmithKline plc.
- AstraZeneca
- Hoffman-La Roche, Ltd.
- Pfizer, Inc.
- Merck & Co., Inc.
- Vascular Biogeneics
- AngioChem, Inc.
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Boston Biomedical, Inc.
- Cantex Pharmaceuticals, Inc.
- Celldex Therapeutics, Inc.
- Cavion LLC
- Coherus BioSciences, Inc.
- Eisai
- Eli Lilly and Company
- Cortice Biosciences, Inc.
- EnGeneIC Ltd.
- GenSpera, Inc.
- ERC Belgium SA
- Genzyme Corporation
- ImmunoCellular Therapeutics, Ltd.
- GW Pharmaceuticals Plc.

Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

Market Purview

Report Description

Market Definition and Scope

Executive Summary

Market Snapshot, By Treatment
Market Snapshot, By Type
Market Snapshot, By Region

Coherent Opportunity Map (COM)

Market Dynamics, Regulations, and Trends Analysis

Market Dynamics

Drivers
Restraints
Market Opportunities

Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter’s Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2026 – 2033, (USD Bn)

Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026– 2033

Segment Trends

Oral Medications

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)

Radiosensitizers

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)

Nitrosoureas Drugs

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)

Chemotherapy

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)

Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2026 – 2033, (USD Bn)

Introduction

Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2026 – 2033
Segment Trends

Grade II or Grade III

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)

Grade IV

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)

Others

Introduction
Market Size and Forecast, and Y-o-Y Growth, 2026–2033, (USD Bn)

Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2026 – 2033, (USD Bn)

Introduction

Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2026–2033
Regional Trends

North America

Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)

U.S.
Canada

Latin America

Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)

Brazil
Mexico
Argentina
Rest of Latin America

Europe

Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)

U.K.
Germany
Italy
France
Spain
Russia
Rest of Europe

Asia Pacific

Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)

China
India
Japan
ASEAN
Australia
South Korea
Rest of Asia Pacific

Middle East

Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 – 2033, (USD Bn)

GCC
Israel
Rest of Middle East

Africa

Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Type, 2026 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2026 – 2033, (USD Bn)

North Africa
Central Africa
South Africa

Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile

GlaxoSmithKline plc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

AstraZeneca

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

F. Hoffman-La Roche, Ltd.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Pfizer, Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Merck & Co., Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Vascular Biogeneics

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

AngioChem, Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Boehringer Ingelheim GmbH

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Bristol-Myers Squibb Company

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Boston Biomedical, Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Cantex Pharmaceuticals, Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Celldex Therapeutics, Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Cavion LLC

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Cavion LLC

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Eisai

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Eli Lilly and Company

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies

Cortice Biosciences, Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Market Strategies

EnGeneIC Ltd.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Market Strategies

GenSpera, Inc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Market Strategies

ERC Belgium SA

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Market Strategies

Genzyme Corporation

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Market Strategies

ImmunoCellular Therapeutics, Ltd.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Market Strategies

GW Pharmaceuticals Plc.

Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Market Strategies

Analyst Views

Section

References
Research Methodology
About Us

Get Instant Access - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now